Ovarian cancer is the most lethal gynecologic malignancy. Despite advances in surgery and chemotherapy, about 80% of patients with advanced-stage disease who achieved complete remission after first-line chemotherapy will ultimately relapse. High rate of recurrence in ovarian cancer is associated with chemoresistance and poor outcome. Recent pieces of evidence have suggested that cancer stem cells may contribute to the development of chemoresistance. Knowledge and understanding of ovarian carcinogenesis and mechanisms of chemoresistance will lead to development of animal models and provide successful therapies in ovarian cancer patients.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand ovarian carcinogenesis, tumor heterogeneity issue, and ovarian cancer stem cells. We are particularly interested in articles describing new insights into ovarian carcinogenesis using animal models; genomic approaches to find driver mutations in ovarian carcinogenesis; molecular pathways associated with chemoresistance in ovarian cancer; the new modalities for characterization of ovarian cancer stem cell. Potential topics include, but are not limited to:

• Recent concepts of ovarian carcinogenesis (Types I, II)
• Serous tubal intraepithelial neoplasm in risk reducing salpingo-oophorectomy specimen
• Genomic approaches to identify driver mutations in ovarian carcinogenesis
• Molecular mechanisms of chemoresistance
• Intratumor heterogeneity in ovarian cancer
• Characterization of ovarian cancer stem cell
• Role of ovarian cancer stem cell in chemoresistance

Before submission, authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/obgyn/oc/ according to the following timetable: